



# Health Research Authority

## NRES Committee London - South East

Bristol Research Ethics Committee Centre  
Level 3, Block B  
Whitefriars,  
Lewins Mead,  
Bristol  
BS1 2NT

Telephone: (0117) 3421382  
Facsimile: (0117) 3420445

17 April 2014

Mr Paul Cartledge  
Research Innovation Services, University of Nottingham  
Kings Meadow Campus, Lenton Lane  
Nottingham NG7 2NR

Dear Mr Cartledge

**Study Title:** Safety and tolerability of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke: a randomised controlled trial

**REC reference:** 08/H1102/112

**Protocol number:** 31350

**EudraCT number:** 2007-006749-42

**Amendment number:** AM29: SA02/14

**Amendment date:** 11 March 2014

Thank you for submitting the above amendment, which was received on 31 March 2014.

Research Site	Principal Investigator / Local Collaborator
Great Western Hospitals NHS Trust, Great Western Hospital, Marlborough Road, Swindon, Wiltshire SN3 6BB	Dr Dr Gopinath Ramadurai
Bedford Hospital NHS Trust, Kempston Road, Bedford, MK42 9DL	Dr Mohammad Wasil
Salford Royal NHS Foundation Trust, North West Hyperacute Stroke Research Centre, ERoom b210, Clinical Science Building, Stott Lane, Salford M6 8HD	Dr Chris Douglass
Heart of England NHS Foundation Trust, Good Hope Hospital, rectory Road, Sutton Coldfield, Birmingham B91 2JL	Dr Arumugam Ravindrane
Heart of England NHS Foundation Trust, Solihull Hospital, Lode Lane, Birmingham B91 2JL	Dr Khaled Elfandi

The amendment relates solely to the addition of new site(s) and/or investigator(s) within the National Health Service (NHS) or Health and Social Care (HSC) in Northern Ireland. The site-specific assessment for the site(s) will therefore form part of the research governance review. The Site-Specific Information (SSI) Form for the site should be included with the application for R&D approval.

On behalf of the Committee, I am pleased to confirm the extension of the favourable opinion to the new site(s) and/or investigator(s), subject to management permission being given by the relevant NHS/HSC R&D office(s) prior to the study starting at the site.

### **Statement of compliance**

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.


The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

**08/H1102/112**

**Please quote this number on all correspondence**

Yours sincerely



**Mr Wai Yeung**  
**Research Ethics Committee (REC) Assistant**

Copy to: *Professor Philip M. W. Bath, University of Nottingham*